Top

Published in:

01-08-2012 | SHORT REPORT

Effects of the novel DNA dependent protein kinase inhibitor, IC486241, on the DNA damage response to doxorubicin and cisplatin in breast cancer cells

Authors: David Davidson, Jeremy Grenier, Veronica Martinez-Marignac, Lilian Amrein, May Shawi, Marc Tokars, Raquel Aloyz, Lawrence Panasci

Published in: Investigational New Drugs | Issue 4/2012

Summary

The purpose of this study was to determine the degree to which the novel DNA-PKcs inhibitor, IC486241 (ICC), synergizes the cytotoxicity of DNA damaging agents in 3 genetically diverse breast cancer cell lines. The sulforhodamine B (SRB) assay was employed as a primary screening method to determine the in-vitro cytotoxicity and the degree of synergy of ICC in combination with the topoisomerase II inhibitor, doxorubicin, or the DNA cross linking agent, cisplatin. Molecular mechanisms underlying drug toxicity were probed using immunostaining and flow cytometry, as well as, the alkaline comet assay to detect DNA damage. In this study, improved cytotoxicity and significant synergy were observed with both anticancer agents in the presence of nontoxic concentrations of ICC. Moreover, ICC decreased doxorubicin-induced DNA-PKcs autophosphorylation on Ser2056 and increased doxorubicin-induced DNA fragmentation. In conclusion, the novel DNA-PKcs inhibitor, ICC, synergistically sensitized 3 breast cancer cell lines to doxorubicin and cisplatin. Enhanced efficacy of doxorubicin was achieved by inhibiting non-homologous end joining resulting in increased accumulation of DNA damage.

Cardoso F, Bedard PL, Winer EP, Pagani O, Senkus-Konefka E, Fallowfield LJ, Kyriakides S, Costa A, Cufer T, Albain KS, Force obotE-MT (2009) International guidelines for management of metastatic breast cancer: combination vs. sequential single-agent chemotherapy. J Natl Cancer Inst 101(17):1174–1181. doi:10.1093/jnci/djp235 CrossRefPubMed

Rabik CA, Dolan ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33(1):9–23CrossRefPubMed

Tewey K, Rowe T, Yang L, Halligan B, Liu L (1984) Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226(4673):466–468. doi:10.1126/science.6093249 CrossRefPubMed

Kuo CC, Liu JF, Chang JY (2006) DNA repair enzyme, O6-methylguanine DNA methyltransferase, modulates cytotoxicity of camptothecin-derived topoisomerase I inhibitors. J Pharmacol Exp Ther 316(2):946–954. doi:10.1124/jpet.105.095919 CrossRefPubMed

Mansour WY, Schumacher S, Rosskopf R, Rhein T, Schmidt-Petersen F, Gatzemeier F, Haag F, Borgmann K, Willers H, Dahm-Daphi J (2008) Hierarchy of nonhomologous end-joining, single-strand annealing and gene conversion at site-directed DNA double-strand breaks. Nucleic Acids Res 36(12):4088–4098CrossRefPubMed

Cowell I, Durkacz B, Tilby M (2005) Sensitization of breast carcinoma cells to ionizing radiation by small molecule inhibitors of DNA-dependent protein kinase and ataxia telangiectsia mutated. Biochem Pharmacol 71:13–20CrossRefPubMed

Dejmek J, Iglehart JD, Lazaro J-B (2009) DNA-dependent protein kinase (DNA-PK)-dependent cisplatin-induced loss of nucleolar facilitator of chromatin transcription (FACT) and regulation of cisplatin sensitivity by DNA-PK and FACT. Mol Cancer Res 7(4):581–591CrossRefPubMed

Willmore E, Elliott SL, Mainou-Fowler T, Summerfield GP, Jackson GH, O'Neil F, Lowe C, Carter A, Harris R, Pettitt AR, Cano-Soumillac C, Griffin RJ, Cowell IG, Austin CA, Durkacz BW (2008) DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia. Clin Cancer Res 14(12):3984–3992CrossRefPubMed

Willmore E, de Caux S, Sunter NJ, Tilby MJ, Jackson GH, Austin CA, Durkacz BW (2004) A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood 103:4659–4665CrossRefPubMed

10.

Shinohara ET, Geng L, Tan J, Chen H, Shir Y, Edwards E, Halbrook J, Kesicki EA, Kashishian A, Hallahan DE (2005) DNA-dependent protein kinase is a molecular target for the development of noncytotoxic rediation-sensitizing drugs. Cancer Res 65(12):4987–4992CrossRefPubMed

11.

Davidson D, Coulombe Y, Martinez-Marignac V, Amrein L, Grenier J, Hodkinson K, Masson J-Y, Aloyz R, Panasci L (2011) Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells. Invest New Drugs: 1–9. doi:10.1007/s10637-010-9626-9

12.

Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe J-P, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo W-L, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10(6):515–527CrossRefPubMed

13.

Elstrodt F, Hollestelle A, Nagel JHA, Gorin M, Wasielewski M, van den Ouweland A, Merajver SD, Ethier SP, Schutte M (2006) BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res 66(1):41–45. doi:10.1158/0008-5472.can-05-2853 CrossRefPubMed

14.

Vichai V, Kirtikara K (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1(3):1112–1116CrossRefPubMed

15.

Berenbaum M (1992) Letter correspondence re: “Greco et al., applications of a new approach for the quantitation of drug synergism to the combination of c/s-diamminedichloroplatinum and 1-tf-d-arabinofuranosylcytosine. Cancer res., 50: 5318–5327, 1990”. Cancer Res 52:4558–4565PubMed

16.

Amrein L, Loignon M, Goulet A-C, Dunn M, Jean-Claude B, Aloyz R, Panasci L (2007) Chlorambucil cytotoxicity in malignant B lymphocytes is synergistically increased by 2-(morpholin-4-yl)-benzo[h]chomen-4-one (NU7026)-mediated inhibition of DNA double-strand break repair via inhibition of DNA-dependent protein kinase. J Pharmacol Exp Ther 321(3):848–855. doi:10.1124/jpet.106.118356 CrossRefPubMed

17.

Olive PL, Banath JP (2006) The comet assay: a method to measure DNA damage in individual cells. Natl Protoc 1(1):23–29CrossRef

18.

Loignon M, Amrein L, Dunn M, Aloyz R (2007) Xrcc3 depletion induces spontaneous DNA breaks and p53-dependent. Cell Cycle 6(5):606–611CrossRef

19.

Yang J, Yingnian Y, Hamrick HE, Duerksen-Hughes J (2003) ATM, ATR and DNA-PK: initiators of the cellular genotoxic stress responses. Carcinogenesis 24(10):1571–1580CrossRefPubMed

20.

Yang C, Betti C, Singh S, Toor A, Vaughan A (2009) Impaired NHEJ function in multiple myeloma. Mutat Res 660:66–73CrossRefPubMed

21.

Lord CJ, Ashworth A (2009) Bringing DNA repair in tumors into focus. Clin Cancer Res 15(10):3241–3243CrossRefPubMed

22.

Kao J, Rosenstein BS, Peters S, Milano MT, Kron SJ (2005) Cellular response to DNA damage. Ann NY Acad Sci 1066:243–258CrossRefPubMed

23.

Durocher D, Jackson PJ (2001) DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? Curr Opin Cell Biol 13:225–231CrossRefPubMed

24.

Bennardo N, Cheng A, Huang N, Stark JM (2008) Alternative-NHEJ is a mechanistically distinct pathway of mammalian chromosome break repair. PLoS Genet 4(6):e1000110CrossRefPubMed

25.

Shrivastav M, Miller CA, de Haro LP, Durant ST, Chen BPC, Chen DJ, Nickoloff JA (2009) DNA-PKcs and ATM co-regulate DNA double-strand break repair. DNA Repair 8:920–929CrossRefPubMed

26.

Park E-J, Chan DW, Park J-H, Oettinger MA, Jongbum K (2003) DNA-PK is activated by nucleosomes and phosphorylates H2AX within the nucleosomes in an acetylation-dependent manner. Nucleic Acids Res 31(23):6819–6827CrossRefPubMed

27.

Nutley BP, Smith NF, Hayes A, Kelland LR, Brunton L, Golding BT, Smith GCM, Martin NMB, Workman P, Raynaud FI (2005) Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026. Br J Cancer 93(10):1011–1018PubMed

28.

Stiff T, O'Driscoll M, Rief N, Iwabuchi K, Lobrich M, Jeggo PA (2004) ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Res 64:2390–2396CrossRefPubMed

Title: Effects of the novel DNA dependent protein kinase inhibitor, IC486241, on the DNA damage response to doxorubicin and cisplatin in breast cancer cells
Authors: David Davidson
Jeremy Grenier
Veronica Martinez-Marignac
Lilian Amrein
May Shawi
Marc Tokars
Raquel Aloyz
Lawrence Panasci
Publication date: 01-08-2012
Publisher: Springer US
Published in: Investigational New Drugs / Issue 4/2012
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-011-9678-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 4/2012

Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer

Cell-growth and migration inhibition of human mesothelioma cells induced by 3-O-Methylfunicone from Penicillium pinophilum and cisplatin

Intrathecal liposomal cytarabine (lipoCIT) administration in patients with leukemic or lymphomatous meningitis

Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status

Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC patients

Synergistic effects of the combination of β-ionone and sorafenib on metastasis of human hepatoma SK-Hep-1 cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer